- Previous Close
0.1050 - Open
0.1050 - Bid 0.1100 x --
- Ask 0.1150 x --
- Day's Range
0.1050 - 0.1100 - 52 Week Range
0.0990 - 0.2200 - Volume
9,454 - Avg. Volume
227,191 - Market Cap (intraday)
15.675M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a protective wrap used to protect repaired injured nerves; NervAlign Nerve Graft, a size-based range of off-the-shelf nerve grafts for the repair of damaged nerves; and NervAlign bionic nerve to produce a replacement nerve that contains shaped ionic polymers, which would enable the stimulation of the distal end of a nerve injury. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
renerve.com.auRecent News: RNV.AX
View MorePerformance Overview: RNV.AX
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNV.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNV.AX
View MoreValuation Measures
Market Cap
15.68M
Enterprise Value
8.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
87.96
Price/Book (mrq)
2.25
Enterprise Value/Revenue
46.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
241.27k
Net Income Avi to Common (ttm)
-3.41M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
6.39M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--